Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Porta, C. G.; Eto, M.; Motzer, R. J.; De Giorgi, U. F. F.; Buchler, T.; Basappa, N. S.; Mendez Vidal, M. J.; Tjulandin, S.; Park, S. H.; Melichar, B.; Hutson, T. E.; Alemany, C.; McGregor, B.; He, C. S.; Perini, R.; Mody, K.; McKenzie, J.; Choueiri, T. K.

authors

Publication Date

  • September 1, 2022

webpage

published in

category

start page

  • S1205

end page

  • +

volume

  • 33

issue

  • 7